Evaluation effect of crocin in cardiac complication due to doxorubicin in patients with breast cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131017015044N5

Enrollment

Registered

2020-02-29

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast of unspecified site

Interventions

Intervention 1: Intervention group: Adding crocin to chemotherapy regimen containing doxorubicin. In the intervention group, patients will receive two capsules of 15 mg crocin daily along with chemoth

Eligibility

Sex/Gender

Female

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Non metastatic breast cancer female patient candidate for adjuvant chemotherapy along with regimen containing doxorubicin Negative HER2 receptor

Exclusion criteria

Exclusion criteria: Unwillingness to enter the study History of taking psychiatric drugs (anti-anxiety drugs and Anti-depressant ) Psychiatric disorders Underlying heart disease heart valve disease

Design outcomes

Primary

Measure	Time frame
Complications of heart failure (shortness of breath, reduced EF ). Timepoint: before treatment and 2.5 and 5 months after treatment. Method of measurement: Echocardiography-Electrocardiography- TPI -ProBNP.	—

Secondary

Measure	Time frame
Other cardiac complications (ischemia). Timepoint: before treatment and 2.5 and 5 months after treatment. Method of measurement: Echocardiography-Electrocardiography- TPI -ProBNP.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Molaei

Mashhad University of Medical Sciences

MolaeiF961@mums.ac.ir+98 51 3846 1518

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026